EDErica Daina

Erica Daina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erica Daina has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN

    by Giliane Nanchen, Maddalena Marasà, Matteo Breno, Carolina Martinatto, Miriam Rigoldi, Marina Noris, Elena Bresin, Sara Gamba, Laura Bottanelli, Zahra Imanifard, et al.

    Key Points: This retrospective study analyzed clinical, histological, and biochemical data from a large cohort of participants with biopsy-proven primary C3 glomerulopathy/immune complex-mediated membranoproliferative GN. C3 glomerulopathy and immune complex-mediated membranoproliferative GN subjects shared most baseline and longitudinal features; 10-year kidney survival did not differ across histological subtypes. Older age at onset and higher proteinuria levels at 1 year from biopsy were the strongest predictors of kidney failure. Background: Membranoproliferative glomerulonephritides (MPGNs) are defined by a typical glomerular histopathological pattern including C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). The overall prognosis is poor and the treatment options remain limited. Outcome predictors and reliable surrogate endpoints are critically needed for interventional trials. Herein, we described the natural history and analyzed clinical, histological and biochemical data from a large cohort of patients with primary C3G/IC-MPGN. Methods: This is a retrospective analysis of patients with biopsy-proven primary C3G or IC-MPGN from the Italian Registry of MPGN. Demographic, clinical and histopathological data, molecular complement profiles, treatment patterns, and outcomes were collected. We performed univariable and multivariable Cox regressions and Kaplan–Meier survival analyses to assess risk associations with kidney disease progression. The composite endpoint included ESKD (defined by either eGFR 2 , initiation of chronic dialysis or kidney transplantation), doubling of serum creatinine at the last available follow-up, or death by kidney-related causes. Results: Of the 349 patients identified, 208 had C3G and 141 IC-MPGN. Females were 41%, and over half were younger than 18 years old at time of biopsy. C3G and IC-MPGN patients shared most baseline and longitudinal features, with IC-MPGN patients presenting with higher baseline proteinuria (median 4.0 versus 2.3 g/24 hours, P < 0.001). Median eGFR at presentation was 83 ml/min per 1.73 m 2 . Twenty-six percent of patients progressed to ESKD over a median follow-up of 5 years from diagnosis. Higher proteinuria levels at 1 year from biopsy, particularly ≥1 g/24 hours, were significantly associated with a higher risk of adverse kidney outcomes. Pediatric onset was associated with better kidney survival, whereas kidney survival at 10 years did not statistically differ across histological subtypes. Complement dysregulation and rare functional variants in complement genes were not associated with outcomes. Conclusions: Our findings from a large and well-characterized cohort of individuals with primary C3G/IC-MPGN identify age at onset and proteinuria levels as associations with kidney survival, a finding that should inform future interventional trials.


  • Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN

    by Malak Ghaddar, Fernando Caravaca-Fontán, Manuel Praga, Gema Fernández-Juárez, Hannah J. Lomax-Browne, H. Terence Cook, Erica Daina, Marina Noris, Giuseppe Remuzzi, Dilshani Induruwage, et al.

    Key Points: Lower eGFR, paraprotein presence, and interstitial fibrosis were associated with a higher risk of kidney outcome. Native disease (versus recurrence post-transplantation), White ethnicity, and lower C4 levels were associated with a lower risk of kidney outcome. A 50% reduction in proteinuria from baseline to a value 2 D: 53%, C-statistic: 0.84 [95% confidence interval, 0.82 to 0.86], integrated calibration index: 0.31) and maintained robustness after internal validation. A 50% reduction in proteinuria from baseline to a value <1 g/d was associated with a lower risk of outcome independent of other risk factors (hazard ratio, 0.35; 95% confidence interval, 0.12 to 0.97). Conclusions: Our study evaluated the baseline clinical and histologic parameters associated with kidney outcomes using the largest C3G/idiopathic IC-MPGN cohort to date. These factors were included in a prediction model to assess individual patient risk. Our results provide an evidence-based definition of proteinuria remission that can be used for patient care and in clinical trials. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2025_08_27_CJASNAugust.20.8.82.mp3


  • Open Access

    Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan

    by Steven D. Podos, Howard Trachtman, Gerald B. Appel, Andrew S. Bomback, Bradley P. Dixon, Jack F.M. Wetzels, H. Terence Cook, Samir V. Parikh, Matthew C. Pickering, James Tumlin, et al.

    Introduction: C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who participated in two phase 2 studies with the factor D (FD) inhibitor, danicopan. Methods: Patients with biopsy-confirmed C3G, proteinuria ≥500 mg/day, and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 were enrolled into two studies (NCT03369236 and NCT03459443). Biomarker analysis was performed for patients with C3G confirmed by central pathology laboratory re-evaluation. Complement and clinical biomarkers, biopsy composite score, and activity and chronicity indices were assessed at baseline and analyzed by pairwise Spearman correlation analysis. Results: Twenty-nine patients were included in the analysis (median [interquartile range] age: 24.0 [10.0] years). Systemic complement AP activation was evident by reduced median concentrations of C3 and C5, elevated sC5b-9, and normal C4, relative to reference ranges. C3 showed strong pairwise correlations with C5 and sC5b-9 (r = 0.80 and −0.73, respectively; p < 0.0001). Baseline Ba and FD concentrations were inversely correlated with eGFR (r = −0.83 and −0.87, respectively; p < 0.0001). Urinary concentrations of sC5b-9 were correlated with both plasma sC5b-9 and proteinuria (r = 0.69 and r = 0.83, respectively; p < 0.0001). Biopsy activity indices correlated strongly with biomarkers of systemic AP activation, including C3 (r = −0.76, p < 0.0001), whereas chronicity indices aligned more closely with eGFR (r = −0.57, p = 0.0021). Conclusion: Associations among complement biomarkers, kidney function, and kidney histology may add to the current understanding of C3G and assist with the characterization of patients with this heterogenous disease.


  • Open Access

    Kidney diseases

    by Erica Daina, Monica Cortinovis, Giuseppe Remuzzi

    Summary: Dysregulation and accelerated activation of the alternative pathway (AP) of complement is known to cause or accentuate several pathologic conditions in which kidney injury leads to the appearance of hematuria and proteinuria and ultimately to the development of chronic renal failure. Multiple genetic and acquired defects involving plasma‐ and membrane‐associated proteins are probably necessary to impair the protection of host tissues and to confer a significant predisposition to AP‐mediated kidney diseases. This review aims to explore how our current understanding will make it possible to identify the mechanisms that underlie AP‐mediated kidney diseases and to discuss the available clinical evidence that supports complement‐directed therapies. Although the value of limiting uncontrolled complement activation has long been recognized, incorporating complement‐targeted treatments into clinical use has proved challenging. Availability of anti‐complement therapy has dramatically transformed the outcome of atypical hemolytic uremic syndrome, one of the most severe kidney diseases. Innovative drugs that directly counteract AP dysregulation have also opened new perspectives for the management of other kidney diseases in which complement activation is involved. However, gained experience indicates that the choice of drug should be tailored to each patient's characteristics, including clinical, histologic, genetic, and biochemical parameters. Successfully treating patients requires further research in the field and close collaboration between clinicians and researchers who have special expertise in the complement system.